Background: Sleep restriction therapy (SRT) is a largely untested single treatment component of
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Introduction
An estimated 20% of adults have trouble falling asleep, experience frequent awakenings during the night, and feel tired in the morning 1 . Despite this, only 6.9% of the population are diagnosed with Chronic Insomnia Disorder 1 . Insomnia is a sleep disorder characterised by the difficulty initiating and/or maintaining sleep, even when substantial sleep opportunity is available, and is often accompanied by daytime impairments (e.g., excessive daytime sleepiness, deficits in attention and concentration) 2, 3 .
At the present time, there are several well-established pharmacological, behavioural and psychological treatments available for insomnia. Cognitive-behavioural therapy for insomnia (CBT-I) uses of a combination of behavioural and psychological therapies to improve insomnia symptoms (e.g., cognitive therapy, stimulus control therapy) and for many years has been considered the gold standard treatment for insomnia 4, 5 . One of the arguably most potent behavioural therapies within CBT-I is sleep restriction therapy 6 .
In a recent meta-analysis, sleep restriction therapy (SRT) was established as an effective standalone treatment for insomnia that can achieve sleep improvements in fewer sessions than CBT-I 6 . SRT involves providing insomnia patients with a new sleep opportunity window that restricts their time in bed to the number of hours they currently spend asleep to avoid spending excessive amounts of time in bed (a key maintaining factor of insomnia) 6 . Restricting the opportunity for sleep to the average amount of time currently spent asleep (e.g., 12 :00 AM to 6:00 AM if average sleep duration = 6 hrs of sleep per night) increases sleep homeostatic pressure across the course of the day/evening, resulting in more consolidated sleep, faster sleep onset latency, and increased sleep efficiency (i.e., percentage of time spent asleep whilst in bed) [6] [7] [8] . These sleep opportunity windows are often altered throughout treatment based on the previous week's sleep efficiency (SE) (i.e., ≥85% SE for the past week means an extra 30 min
of time in bed is afforded, ≤85% SE, 30 min less time in bed). However, an recent consensus states that sleep opportunity windows should not be reduced to <5 hrs a night to protect against excessive daytime sleepiness 6,9 , since this is often reported as a prominent side effect during the acute phase of SRT 3, 10, 11 .
During the acute stage of SRT (i.e., first couple of weeks), many recipients report experiencing negative daytime functioning side effects compared to pre-treatment 3 . One study that collected audio diary entries and conducted interviews with 18 insomnia participants undergoing SRT found that most reported feeling exhausted and irritable, having reduced motivation, and experienced difficulty with concentration and memory 3 . However, the study did not use any standardised measures of daytime sleepiness (e.g., Epworth Sleepiness Scale
[ESS]). Of concerning to patients and clinicians is that more than one third of their sample selfreported compromised driving abilities while undergoing SRT (i.e., difficulty maintaining wakefulness, slowed reaction times, concentration impairment) 3 . Despite this, very few studies have measured driving performance in people undergoing SRT for insomnia.
A later study by Kyle et al. (2014) 11 administered the ESS to 16 insomnia patients receiving SRT and found increased daytime sleepiness in the initial 2 weeks of treatment. This daytime sleepiness was reflected in impaired objective performance on a reaction time task 11 .
Although some studies have used tasks sensitive to attentional lapses such as the psychomotor vigilance Task (PVT) 11, 12 , there is a lack of literature focusing on inhibitory control and concurrent tasking (i.e., halting a pending thought or action to start another) for those undergoing SRT, which are arguably important cognitive mechanisms for safe driving 3 .
Consequently, the current study sought to determine whether insomnia patients undergoing SRT experienced side effects that could impair their functioning (i.e., daytime sleepiness, reaction time, inhibitory control) and their driving performance. Despite SRT M A N U S C R I P T A C C E P T E D 
Materials
Diagnostic assessment measure
The diagnostic assessment was in the form of a semi-structured interview based on diagnostic criteria based on the ICSD- 
Sleep Diary
Participants were asked to complete a pen-and-paper sleep diary daily, each week, over pre-treatment, and 2 weeks of SRT. The sleep diary assisted in confirming the insomnia diagnosis and differential diagnosis of other sleep disorders (e.g., circadian rhythm disorders) 16 .
During treatment, sleep diaries were also used to check participants' compliance with time in bed instructions. The sleep diary provided subjective measures of bedtime, and final rise times, time of the sleep attempt, sleep onset latency, wake after sleep onset, time in bed, total sleep time, and sleep efficiency. Thus, the sleep diary used in the present study overlapped with the core consensus sleep diary [17] [18] . Sleep diaries are a valid and reliable method for assessing changes in sleep and insomnia treatment outcomes 16, 19 .
Daytime Sleepiness
The Epworth Sleepiness Scale (ESS) is an 8-item questionnaire, used to assess daytime sleepiness in a variety of situations over the given day 20 . The ESS was used to screen for ineligible participants (ESS scores > 10), track daytime sleepiness, and used as a safety measure The Go/NoGo task is a computerised test used as a measure of speed accuracy and inhibition 21 . Participants were required to respond to "Go" stimuli (i.e., the letter 'M')
appearing on a computer screen as quickly as possible by tapping the spacebar, yet avoid pressing the spacebar when a "No" stimulus was presented (i.e., the letter 'W'). Each letter was displayed for 0.216 sec and the interval between each trial varied between 1300-1700ms, with the task lasting 4 min. If participants failed to identify a "Go" stimulus after 500ms, a tone sounded, signalling they had missed the stimulus. Reaction times measured their correct decision speed, with additional measures of omission accuracy (responses to Go, 'M') and commission accuracy (responses to NoGo, 'W') [22] [23] .
Driving Performance
The AusEd driving simulator is a computer-based task designed to measure driving performance 24 . A standard PC computer was fitted with a steering wheel and brake/acceleration apparatus. Steering deviation (in centimetres), speed deviation (in km/h), 
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Results
Manipulation Check and Sleep Outcomes
Linear mixed-model (LMM) regression analyses were performed on time in bed (TIB) to establish whether insomnia participants complied with SRT instructions, as well as total sleep time (TST) to observe whether sleep had reduced following SRT. LMMs were employed as opposed to ANOVAs as the former analytical technique has the ability to model change in missing data points (i.e., compensate for missing data) 25 . An AR(1) model was used in LMM's as the study employed a repeated measures time-based model and to also compensate for variability in smaller samples 26 .
Insomnia participants complied with a reduction in TIB, evidenced by a significant decrease in over time F(1,2)=8.52, p=.002. As seen in Table 1 Table 2 about here >
Discussion
The aim of the current study was to investigate subjective and objective changes in daytime functioning and performance during the acute phase (first 2 weeks) of sleep restriction therapy 
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
11
We anticipated that self-reported daytime sleepiness (ESS scores) would increase from pre-treatment to post-treatment (i.e., the acute 2 weeks of SRT). However, this was not observed. This prediction was based on the premise that insomnia patients may have experienced reductions in TST, as well as results from previous studies 11 . The lack of change in our participants' self-reported daytime sleepiness, even in response to a mean 32-min reduction in TST, aligns with previous studies of stable daytime sleepiness after 1 week of ~30-min less TST in good sleepers 27 . In contrast, TST reductions >1hr in good sleepers 28 and insomnia patients 11 over an approximately 2-week period produce increases in daytime sleepiness. Taken together, the findings suggest that a reduction of ~30-min of TST during the acute phase of SRT (ie, first 2 weeks) is not potent enough to result in changes in patients' perceived daytime sleepiness. If anything, we note no change after 1 week of SRT (d=0.02), yet a small decrease (d=0.44) from mid-treatment (i.e., after 1 week of SRT) to post-treatment (i.e., after 2 weeks of SRT), suggesting a reduced risk for insomnia patients undergoing SRT.
However, an important contribution from the present study is systemically examining multiple outcome measures, so as not to rely solely on patients' ESS scores.
The Go/NoGo task was an objective test of participants' reaction times and inhibition 21 .
Although previous studies found increased reaction times (using the PVT) following sleep restriction in good sleepers 12, 29 and from SRT for insomnia 11 , the present study did not find such deficits. Even in the context of a 32-min TST reduction, effect sizes during SRT were virtually nil (ds=0.00-0.03). Similarly, both omission and commission accuracy did not significantly change, with negligible effects for omission accuracy (i.e., accidently responding to 'NoGo' stimulus;
ds=0.06-0.10). Although small effects were found for omission accuracy (i.e., correctly responding to 'Go' stimulus; ds=0. 23-0.27) , the actual percentage change was within 1% which is not meaningful).
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Driving performance was the second objective task used during the acute phase of SRT, as insomnia patients undergoing SRT self-report driving difficulties 3 yet to our knowledge this has not been objectively verified. Contrary to expectations, reaction time, speed deviation, steering deviation and crash frequency did not deteriorate over the treatment period. Although small effects occurred during SRT (i.e., Δreaction time=0.06ms; Δsteering deviation=4cm; Δspeed deviation<0.2km/hr), these are not meaningful. Previous studies using the AusEd driving simulator have reported deficits in driving parameters, however these were observed following a significant reduction in total sleep time and/or consumption of alcohol in good sleepers (e.g., TIB=5 hrs) 30, 31 . Given insomnia patients' self-reports of impaired driving whilst undergoing SRT, more data are required to more confidently claim that it is safe for such patients to drive during the acute phases of treatment.
Implications
The present study provides preliminary evidence to suggest SRT may be a safe clinical intervention for people with insomnia. The chances of dozing, reaction times, inhibitory control and driving performance remained relatively stable after 2 weeks of SRT. This appears to occur despite a reduction of ~30-min (or less) sleep duration. Insomnia patients' self-reports of driving performance may not mirror objective assessments of driving performance, which supports theoretical models of distorted daytime performance deficits 32 . However at this stage, we reserve the use of these preliminary findings to psychoeducation (over behavioural experiments) during treatment. Although we did not objectively measure TST during SRT like previous studies 11 , the use of polysomnography or wrist actigraphy is arguably not the norm in clinical practice, whereas sleep diaries are more accessible. This suggests the findings from the present study are applicable broadly to clinicians performing SRT. Likewise, while our sample may be considered small (N=16), it is comparable to the two other studies of SRT as a stand-M A N U S C R I P T
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13 alone treatment for insomnia (N=16-18) 3, 11 , and it included a range of mental health and medical co-morbidities that increases the chances of these implications being applicable in clinical practice [33] [34] [35] .
Limitations and Future Directions
Research to answer the question "Is sleep restriction therapy safe?" would be enhanced by further replication, using sample sizes larger than that in the present study (N=16) and others (N=16-18) 3, 11 , and including a control group (e.g., waitlist control). We do not necessarily
suggest larger samples to be tested in order to detect statistical significance (as we believe the meaningfulness of changes is important), but more so that findings can be generalised better to insomnia patients undergoing SRT. It is not exactly known how much sleep patients obtained during the present study, as no objective measures were used 11, [36] [37] . Therefore, future studies are recommended to use both subjective (sleep diary) and objective (wrist actigraphy) measures of sleep quantity during SRT. Simultaneous measurement would also address the issue that a significant proportion of people with insomnia experience sleep misperception (i.e., under-estimate TST) 38 , which could lead to more accurate implementation of SRT. We also note that the present study used a 15-min driving simulator, so future studies should consider extending the duration (e.g., 60 min) 24 . This will give an indication as to whether or not sustained attention whilst driving deteriorates, or whether it remains the same over a longer period of time. • Applying SRT as per recent guidelines led to a mean decrease in sleep duration of 32 minutes.
• No significant changes in sleepiness, reaction times or driving performance were found whilst insomnia patients underwent 2 weeks of SRT.
